The Use of Integrase Strand Transfer Inhibitors to Treat HIV in Pregnancy. (24th June 2021)

• Record Type: Journal Article
• Authors: Nissim, Oriel; Lazenby, Gweneth B.
• Is Part Of: Journal of midwifery & women's health. Volume 66:Number 3(2021)
• Page Start: 403
• Page End: 406
• Publication Date: 2021-06-24
• Subjects: pregnancy -- HIV -- integrase inhibitors -- dolutegravir -- raltegravir -- elvitegravir -- bictegravir; Midwives -- Periodicals; Obstetrics -- Periodicals; Women's health services -- Periodicals; 618.2
• DOI: 10.1111/jmwh.13249
• Languages: English
• ISSNs: 1526-9523

Abstract

Abstract: For pregnant women with HIV, antiretroviral therapy (ART) plays a key role in prevention of perinatal transmission. Newer antiretroviral regimens now contain integrase strand transfer inhibitors, which have been found to rapidly suppress HIV viral load in nonpregnant women; however, there are limited data for use in pregnancy. Here, we present the case of a pregnant woman with well‐controlled HIV on a well‐tolerated prepregnancy regimen of bictegravir, emtricitabine, and tenofovir alafenamide. As there are limited safety data on bictegravir in pregnancy, this ART regimen was changed to a preferred regimen for pregnancy. In the second trimester, because of adverse effects from the new ART regimen and after a risk‐benefit discussion, the patient restarted the original regimen. She was able to maintain viral suppression until giving birth.